title: [Intravitreous injection of bevacizumab and C3F8 gas for the treatment of submacular hemorrhage due to age-related macular degeneration: case reports].
abstract: The purpose of this case series is to describe if the intravitreal use of bevacizumab and perfluoropropane gas (C3F8) would be beneficial to the displacement of subretinal hemorrhage in patients with age-related macular degeneration (AMD). A retrospective study of 5 eyes that received concurrent intravitreal injection of bevacizumab and C3F8 was performed. The results were graded according to blood displacement under the fovea, best final visual acuity and intraoperative complications. At the initial presentation, mean age of patients was 72.6 +/- 8.9 years-old and duration of symptoms was 13 +/- 9.7 days. From the 5 patients, 3 (60%) were male and 2 (40%) female. The success of submacular hemorrhage full displacement was achieved in 4 patients. The mean preoperative visual acuity (VA) was 1.12 +/- 0.34 logMAR and the mean postoperative VA was 0.92 +/- 0.4 logMAR. No cases of retinal detachment, endophthalmitis, vitreous hemorrhage, uveitis, cataracts and increased intraocular pressure were noted during the follow-up period. Intravitreal bevacizumab and C3F8 injection, associated to prone position can be a valuable therapeutic option for eyes with neovascular age-related macular degeneration and subretinal hemorrhage to the blood displacement out of the foveal area.
authors.affiliation: Setor de Retina e Vítreo, Hospital das Clínicas da Universidade de São Paulo - São Paulo (SP) - Brasil. danielferraz1@hotmail.com
authors.forename: Daniel Araújo
authors.initials: DA
authors.lastname: Ferraz
authors.forename: Gláucio Luciano
authors.initials: GL
authors.lastname: Bressanim
authors.forename: Celso
authors.initials: C
authors.lastname: Morita
authors.forename: Walter Yukihiko
authors.initials: WY
authors.lastname: Takahashi
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005466:Fluorocarbons / Q000008:administration & dosage*; D005584:Fovea Centralis; D006801:Humans; D056965:Injections, Intraocular / Q000379:methods; D008268:Macular Degeneration / Q000150:complications*; D008297:Male; D008875:Middle Aged; D012166:Retinal Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D012189:Retrospective Studies; D012720:Severity of Illness Index; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005466:Fluorocarbons; D000068258:Bevacizumab; C042852:perflutren